Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.51 |
| ▸ | JAK2 | O60674 | 8/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | WEE1 | P30291 | 2/20 | 0.51 |
| ▸ | BUB1B | O60566 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22931705 | 0.92 | BRD4 (0.49) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22931673 | 0.89 | BRD4 (0.51) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22931677 | 0.88 | BRD4 (0.66) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22931672 | 0.85 | BRD4 (0.54) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22931678 | 0.85 | BRD4 (0.57) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22932132 | 0.84 | BRD4 (0.65) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22932131 | 0.83 | BRD4 (0.63) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22931699 | 0.83 | BRD4 (0.62) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22931674 | 0.83 | BRD4 (0.51) | BRD4JAK2FLT3WEE1BUB1B | |
| SCHEMBL22932174 | 0.82 | TTK (0.53) | BRD4JAK2FLT3WEE1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006031-A1 | DIHYDRO-PYRROLO-PYRIMIDINE SELECTIVE JAK2 INHIBITOR | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2022-06-01 | — | — | EP | disclosed |
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2021017384-A1 | DIHYDRO-PYRROLO-PYRIMIDINE SELECTIVE JAK2 INHIBITOR | 上海勋和医药科技有限公司 | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | JAK2, JAK1, JAK3 | BRD4 115/4885JAK2 1/4885FLT3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.